Design of a Novel Peptide Inhibitor of HIV Fusion That Disrupts the Internal Trimeric Coiled-coil of gp41*

The pre-hairpin intermediate of gp41 from the human immunodeficiency virus (HIV) is the target for two classes of fusion inhibitors that bind to the C-terminal region or the trimeric coiled-coil of N-terminal helices, thereby preventing formation of the fusogenic trimer of hairpins. Using rational design, two 36-residue peptides, N36Mut(e,g) and N36Mut(a,d), were derived from the parent N36 peptide comprising the N-terminal helix of the gp41 ectodomain (residues 546–581 of HIV-1 envelope), characterized by analytical ultracentrifugation and CD, and assessed for their ability to inhibit HIV fusion using a quantitative vaccinia virus-based fusion assay. N36Mut(e,g) contains nine amino acid substitutions designed to disrupt interactions with the C-terminal region of gp41 while preserving contacts governing the formation of the trimeric coiled-coil. N36Mut(a,d) contains nine substitutions designed to block formation of the trimeric coiled-coil but retains residues that interact with the C-terminal region of gp41. N36Mut(a,d) is monomeric, is largely random coil, does not interact with the C34 peptide derived from the C-terminal region of gp41 (residues 628–661), and does not inhibit fusion. The trimeric coiled-coil structure is therefore a prerequisite for interaction with the C-terminal region of gp41. N36Mut(e,g) forms a monodisperse, helical trimer in solution, does not interact with C34, and yet inhibits fusion about 50-fold more effectively than the parent N36 peptide (IC50∼ 308 nm versus ∼16 μm). These results indicate that N36Mut(e,g) acts by disrupting the homotrimeric coiled-coil of N-terminal helices in the pre-hairpin intermediate to form heterotrimers. Thus N36Mut(e,g)represents a novel third class of gp41-targeted HIV fusion inhibitor. A quantitative model describing the interaction of N36Mut(e,g) with the pre-hairpin intermediate is presented.

[1]  T. Matthews,et al.  Peptides corresponding to a predictive alpha-helical domain of human immunodeficiency virus type 1 gp41 are potent inhibitors of virus infection. , 1994, Proceedings of the National Academy of Sciences of the United States of America.

[2]  Eric Hunter,et al.  Potent suppression of HIV-1 replication in humans by T-20, a peptide inhibitor of gp41-mediated virus entry , 1998, Nature Medicine.

[3]  T. Oas,et al.  A synthetic peptide inhibitor of human immunodeficiency virus replication: correlation between solution structure and viral inhibition. , 1992, Proceedings of the National Academy of Sciences of the United States of America.

[4]  P S Kim,et al.  Evidence that a prominent cavity in the coiled coil of HIV type 1 gp41 is an attractive drug target. , 1998, Proceedings of the National Academy of Sciences of the United States of America.

[5]  R. Blumenthal,et al.  Conformational Changes in Cell Surface HIV-1 Envelope Glycoproteins Are Triggered by Cooperation between Cell Surface CD4 and Co-receptors* , 1998, The Journal of Biological Chemistry.

[6]  S. Harrison,et al.  Structural basis for membrane fusion by enveloped viruses. , 1999, Molecular membrane biology.

[7]  Michael S. Kay,et al.  Protein Design of an HIV-1 Entry Inhibitor , 2001, Science.

[8]  E. Freed,et al.  The Role of Human Immunodeficiency Virus Type 1 Envelope Glycoproteins in Virus Infection (*) , 1995, The Journal of Biological Chemistry.

[9]  Y. Shai,et al.  Inhibition of HIV-1 entry before gp41 folds into its fusion-active conformation. , 2000, Journal of molecular biology.

[10]  S. Peisajovich,et al.  SIV gp41 binds to membranes both in the monomeric and trimeric states: consequences for the neuropathology and inhibition of HIV infection. , 2001, Journal of molecular biology.

[11]  K. Tan,et al.  Atomic structure of a thermostable subdomain of HIV-1 gp41. , 1997, Proceedings of the National Academy of Sciences of the United States of America.

[12]  P S Kim,et al.  Mechanisms of viral membrane fusion and its inhibition. , 2001, Annual review of biochemistry.

[13]  Stephen C. Blacklow,et al.  A trimeric structural domain of the HIV-1 transmembrane glycoprotein , 1995, Nature Structural Biology.

[14]  Stephen J. Perkins,et al.  Protein volumes and hydration effects , 1986 .

[15]  G. Clore,et al.  Monomer‐trimer equilibrium of the ectodomain of SIV gp41: Insight into the mechanism of peptide inhibition of HIV infection , 1999, Protein science : a publication of the Protein Society.

[16]  S. Harrison,et al.  Atomic structure of the ectodomain from HIV-1 gp41 , 1997, Nature.

[17]  C. Weiss,et al.  Capture of an early fusion-active conformation of HIV-1 gp41 , 1998, Nature Structural Biology.

[18]  P. S. Kim,et al.  Design of potent inhibitors of HIV-1 entry from the gp41 N-peptide region , 2001, Proceedings of the National Academy of Sciences of the United States of America.

[19]  P. S. Kim,et al.  HIV Entry and Its Inhibition , 1998, Cell.

[20]  G. Böhm,et al.  Quantitative analysis of protein far UV circular dichroism spectra by neural networks. , 1992, Protein engineering.

[21]  K. Salzwedel,et al.  Sequential CD4-Coreceptor Interactions in Human Immunodeficiency Virus Type 1 Env Function: Soluble CD4 Activates Env for Coreceptor-Dependent Fusion and Reveals Blocking Activities of Antibodies against Cryptic Conserved Epitopes on gp120 , 2000, Journal of Virology.

[22]  A. Gronenborn,et al.  Three‐dimensional solution structure of the 44 kDa ectodomain of SIV gp41 , 1998, The EMBO journal.

[23]  S. Durell,et al.  Dilation of the Human Immunodeficiency Virus–1 Envelope Glycoprotein Fusion Pore Revealed by the Inhibitory Action of a Synthetic Peptide from gp41 , 1998, The Journal of cell biology.

[24]  S Neidle Computing in biology - an overview : Computing in biological science Geisow, M J and Barrett, A N (eds) Elsevier Biomedical Press (1983) $60 , 1983 .

[25]  P S Kim,et al.  Crystal structure of the simian immunodeficiency virus (SIV) gp41 core: conserved helical interactions underlie the broad inhibitory activity of gp41 peptides. , 1998, Proceedings of the National Academy of Sciences of the United States of America.

[26]  A. Trkola,et al.  Co-receptors for HIV-1 entry. , 1997, Current opinion in immunology.

[27]  A. Gronenborn,et al.  The extracellular domain of immunodeficiency virus gp41 protein: Expression in Escherichia coli, purification, and crystallization , 1997, Protein science : a publication of the Protein Society.

[28]  C. Bewley,et al.  Design and Properties of NCCG-gp41, a Chimeric gp41 Molecule with Nanomolar HIV Fusion Inhibitory Activity* , 2001, The Journal of Biological Chemistry.